Lexeo Therapeutics FA trial update - Ataxia UK

Lexeo Therapeutics FA trial update

Post Published: June 15, 2023

Lexeo Therapeutics is a company developing gene therapy for people with FA cardiomyopathy. They recently announced the completion of the first cohort in their Phase I/II trial, testing their gene therapy called LX2006.  

In the first cohort, LX2006 was well tolerated with no unexpected events observed. Based on this, they have begun dosing the second cohort of participants. This is a 52-week trial taking place in America. They expect results from this trial in the first half of 2024. 

Read more in the Lexeo Therapeutics press release.

Subscribe To Our Newsletter

fundraise image


Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.

Donate Image


To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia

Volunteer Image


Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.

Donate Now
Scroll to Top